KR101113084B1 - 파론노세트론의 액체 약제학적 제제 - Google Patents

파론노세트론의 액체 약제학적 제제 Download PDF

Info

Publication number
KR101113084B1
KR101113084B1 KR1020057014093A KR20057014093A KR101113084B1 KR 101113084 B1 KR101113084 B1 KR 101113084B1 KR 1020057014093 A KR1020057014093 A KR 1020057014093A KR 20057014093 A KR20057014093 A KR 20057014093A KR 101113084 B1 KR101113084 B1 KR 101113084B1
Authority
KR
South Korea
Prior art keywords
delete delete
palonosetron
acid
solution
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057014093A
Other languages
English (en)
Korean (ko)
Other versions
KR20050104363A (ko
Inventor
기올기아 칼데라리
단니엘 보나데오
로베르타 카넬리아
리칼도 브라그리아
엔리코 브라그리아
Original Assignee
헬신 헬쓰케어 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101113084(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 헬신 헬쓰케어 에스.에이. filed Critical 헬신 헬쓰케어 에스.에이.
Publication of KR20050104363A publication Critical patent/KR20050104363A/ko
Application granted granted Critical
Publication of KR101113084B1 publication Critical patent/KR101113084B1/ko
Assigned to 로쉐 팔로 알토 엘엘씨 reassignment 로쉐 팔로 알토 엘엘씨 권리의 일부이전등록 Assignors: 헬신 헬쓰케어 에스.에이.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020057014093A 2003-01-30 2004-01-30 파론노세트론의 액체 약제학적 제제 Ceased KR101113084B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30
US60/444,351 2003-01-30
PCT/EP2004/000888 WO2004067005A1 (en) 2003-01-30 2004-01-30 Liquid pharmaceutical formulations of palonosetron

Publications (2)

Publication Number Publication Date
KR20050104363A KR20050104363A (ko) 2005-11-02
KR101113084B1 true KR101113084B1 (ko) 2012-02-15

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057014093A Ceased KR101113084B1 (ko) 2003-01-30 2004-01-30 파론노세트론의 액체 약제학적 제제

Country Status (41)

Country Link
US (9) US7947724B2 (cg-RX-API-DMAC7.html)
EP (2) EP2008659A1 (cg-RX-API-DMAC7.html)
JP (2) JP5461763B2 (cg-RX-API-DMAC7.html)
KR (1) KR101113084B1 (cg-RX-API-DMAC7.html)
CN (2) CN1758911A (cg-RX-API-DMAC7.html)
AP (1) AP2110A (cg-RX-API-DMAC7.html)
AR (1) AR042977A1 (cg-RX-API-DMAC7.html)
AT (1) ATE410167T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004208505C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407121B8 (cg-RX-API-DMAC7.html)
CA (5) CA2573194A1 (cg-RX-API-DMAC7.html)
CR (1) CR7921A (cg-RX-API-DMAC7.html)
CY (1) CY1108660T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004016967D1 (cg-RX-API-DMAC7.html)
DK (1) DK1601359T3 (cg-RX-API-DMAC7.html)
EA (1) EA014066B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055938A (cg-RX-API-DMAC7.html)
ES (1) ES2315635T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20084445B (cg-RX-API-DMAC7.html)
HR (1) HRP20050676B1 (cg-RX-API-DMAC7.html)
IL (1) IL169859A (cg-RX-API-DMAC7.html)
IS (1) IS7984A (cg-RX-API-DMAC7.html)
JO (1) JO2735B1 (cg-RX-API-DMAC7.html)
MA (1) MA27710A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008028A (cg-RX-API-DMAC7.html)
MY (1) MY144036A (cg-RX-API-DMAC7.html)
NO (1) NO329500B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ541533A (cg-RX-API-DMAC7.html)
PA (1) PA8594801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050066A1 (cg-RX-API-DMAC7.html)
PL (1) PL378398A1 (cg-RX-API-DMAC7.html)
PT (1) PT1601359E (cg-RX-API-DMAC7.html)
PY (1) PY0401585A (cg-RX-API-DMAC7.html)
RS (1) RS20050578A (cg-RX-API-DMAC7.html)
SI (1) SI1601359T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN05180A1 (cg-RX-API-DMAC7.html)
TW (1) TWI342212B (cg-RX-API-DMAC7.html)
UA (1) UA90449C2 (cg-RX-API-DMAC7.html)
UY (1) UY28175A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004067005A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506917B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP2499137A1 (en) 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2013057554A2 (en) 2011-10-18 2013-04-25 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
HRP20200196T1 (hr) * 2016-06-06 2020-05-01 Helsinn Healthcare Sa Fiziološki balansirane injektabilne formulacije fosnetupitanta
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US11433021B2 (en) * 2018-01-12 2022-09-06 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) * 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物
TW202428273A (zh) 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202333A (en) 1989-11-28 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic 5-HT3 receptor antagonists
US5854270A (en) 1994-11-22 1998-12-29 Glaxo Wellcome Inc. Oral compositions containing ondansetron

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3687080T2 (de) 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
ES2149305T3 (es) 1991-05-03 2000-11-01 Searle & Co Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
BR9914799A (pt) * 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
CA2446837C (en) 2001-05-11 2012-01-03 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
AU2003237657A1 (en) 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ES2285407T3 (es) 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202333A (en) 1989-11-28 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic 5-HT3 receptor antagonists
US5854270A (en) 1994-11-22 1998-12-29 Glaxo Wellcome Inc. Oral compositions containing ondansetron

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anesth. Analg. 1998, Vol. 87, pp. 462-467
International Journal of Pharmaceutics, 1995, Vol. 121, pp. 95-105

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
US9877959B2 (en) 2013-12-23 2018-01-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
KR101920322B1 (ko) 2013-12-23 2018-11-20 주식회사 삼양바이오팜 팔로노세트론을 함유하는 액상 약학 조성물의 보관 안정성을 증가시키는 방법

Also Published As

Publication number Publication date
US7947724B2 (en) 2011-05-24
US9308266B2 (en) 2016-04-12
DE602004016967D1 (de) 2008-11-20
AR042977A1 (es) 2005-07-13
CN1758911A (zh) 2006-04-12
TW200418517A (en) 2004-10-01
CR7921A (es) 2006-02-07
US20110192493A1 (en) 2011-08-11
US20140039000A1 (en) 2014-02-06
NO20053987L (no) 2005-08-26
AP2110A (en) 2010-03-01
HRP20050676B1 (hr) 2013-02-28
EP1601359B1 (en) 2008-10-08
US20160317440A1 (en) 2016-11-03
PT1601359E (pt) 2008-11-03
CN102813621A (zh) 2012-12-12
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
MA27710A1 (fr) 2006-01-02
TNSN05180A1 (en) 2007-06-11
NZ541533A (en) 2008-12-24
JP2011236242A (ja) 2011-11-24
HRP20050676A2 (en) 2005-10-31
ECSP055938A (es) 2006-03-01
AP2005003382A0 (en) 2005-09-30
BRPI0407121A (pt) 2006-01-10
US9457020B2 (en) 2016-10-04
TWI342212B (en) 2011-05-21
BRPI0407121B1 (pt) 2018-07-17
PY0401585A (es) 2009-12-01
NO329500B1 (no) 2010-11-01
US20140097114A1 (en) 2014-04-10
US20130267553A1 (en) 2013-10-10
US7947725B2 (en) 2011-05-24
PA8594801A1 (es) 2004-09-16
US7960424B2 (en) 2011-06-14
EP1601359A1 (en) 2005-12-07
IL169859A (en) 2014-11-30
KR20050104363A (ko) 2005-11-02
JP5551658B2 (ja) 2014-07-16
AU2004208505B2 (en) 2009-09-03
MY144036A (en) 2011-07-29
EA200501203A1 (ru) 2006-06-30
CA2514224A1 (en) 2004-08-12
CA2573363A1 (en) 2004-08-12
CY1108660T1 (el) 2014-04-09
JO2735B1 (en) 2013-09-15
ATE410167T1 (de) 2008-10-15
EP2008659A1 (en) 2008-12-31
SI1601359T1 (sl) 2009-04-30
US8598218B2 (en) 2013-12-03
WO2004067005A1 (en) 2004-08-12
GEP20084445B (en) 2008-08-10
IS7984A (is) 2005-08-15
PE20050066A1 (es) 2005-04-20
US20060167073A1 (en) 2006-07-27
PL378398A1 (pl) 2006-04-03
US20060167071A1 (en) 2006-07-27
AU2004208505C1 (en) 2015-10-01
RS20050578A (sr) 2007-09-21
US20060069114A1 (en) 2006-03-30
AU2004208505A2 (en) 2004-08-12
ES2315635T3 (es) 2009-04-01
JP5461763B2 (ja) 2014-04-02
UY28175A1 (es) 2004-09-30
ZA200506917B (en) 2006-08-30
DK1601359T3 (da) 2009-01-05
CA2573241A1 (en) 2004-08-12
MXPA05008028A (es) 2006-01-27
AU2004208505A1 (en) 2004-08-12
US8518981B2 (en) 2013-08-27
UA90449C2 (ru) 2010-05-11
BRPI0407121B8 (pt) 2021-06-29
EA014066B1 (ru) 2010-08-30
JP2006516583A (ja) 2006-07-06
HK1076401A1 (en) 2006-01-20
US20160000773A1 (en) 2016-01-07
CA2573228A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
JP5551658B2 (ja) パロノセトロン液状医薬製剤
US9457021B1 (en) Liquid pharmaceutical formulations of palonosetron
US20060167072A1 (en) Liquid pharmaceutical formulations of palonosetron
HK1076401B (en) Liquid pharmaceutical formulations of palonosetron

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050729

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090129

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101208

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20111205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120131

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20141231

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20141231

Start annual number: 4

End annual number: 4

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20150313

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20120131

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20150313

Decision date: 20160907

Appeal identifier: 2015100000951

FPAY Annual fee payment

Payment date: 20160104

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160104

Start annual number: 5

End annual number: 5

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20160404

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20120131

Comment text: Registration of Establishment

Decision date: 20160907

Request date: 20160404

Appeal identifier: 2016100000844

Appeal kind category: Confirmation of the scope of right_defensive

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20160412

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20120131

Comment text: Registration of Establishment

Decision date: 20160907

Request date: 20160412

Appeal identifier: 2016100000938

Appeal kind category: Confirmation of the scope of right_defensive

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100000844; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160404

Effective date: 20160907

Free format text: TRIAL NUMBER: 2015100000951; TRIAL DECISION FOR INVALIDATION REQUESTED 20150313

Effective date: 20160907

Free format text: TRIAL NUMBER: 2016100000938; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160412

Effective date: 20160907

PJ1301 Trial decision

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20160412

Decision date: 20160907

Appeal identifier: 2016100000938

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20160404

Decision date: 20160907

Appeal identifier: 2016100000844

Patent event code: PJ13011S05D

Patent event date: 20160907

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ13011S02D

Patent event date: 20160907

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20150313

Decision date: 20160907

Appeal identifier: 2015100000951

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2016200007473; INVALIDATION

PJ2001 Appeal

Patent event date: 20160907

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Patent event date: 20160907

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S02I

Appeal kind category: Invalidation

Decision date: 20170901

Appeal identifier: 2016200007473

Request date: 20161006

FPAY Annual fee payment

Payment date: 20170102

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170102

Start annual number: 6

End annual number: 6

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20170428

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20120131

Comment text: Registration of Establishment

Decision date: 20180420

Request date: 20170428

Appeal identifier: 2017100001359

Appeal kind category: Confirmation of the scope of right_defensive

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20170615

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20120131

Comment text: Registration of Establishment

Decision date: 20170712

Request date: 20170615

Appeal identifier: 2017100001846

Appeal kind category: Confirmation of the scope of right_defensive

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20170712

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2017100001846

Request date: 20170615

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20170712

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2017300002260; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

PJ2002 Appeal before the supreme court

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event date: 20160907

Patent event code: PJ20021S05I

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event date: 20160907

Patent event code: PJ20021S02I

Request date: 20170925

Appeal identifier: 2017300002260

Appeal kind category: Invalidation

Decision date: 20180111

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016200007473; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20161006

Effective date: 20170901

PJ1302 Judgment (patent court)

Patent event date: 20171130

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20161006

Decision date: 20170901

Appeal identifier: 2016200007473

Appeal kind category: Invalidation

FPAY Annual fee payment

Payment date: 20180110

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180110

Start annual number: 7

End annual number: 7

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2017300002260; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20170925

Effective date: 20180111

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20180130

Patent event code: PJ13031S01D

Decision date: 20180111

Appeal kind category: Invalidation

Request date: 20170925

Appeal identifier: 2017300002260

J221 Remand (intellectual property tribunal)

Free format text: TRIAL NUMBER: 2018130000013; REMAND (INTELLECTUAL PROPERTY TRIBUNAL) FOR INVALIDATION

PJ2201 Remand (intellectual property tribunal)

Request date: 20180202

Appeal kind category: Invalidation

Appeal identifier: 2018130000013

Decision date: 20180228

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20180206

J301 Trial decision

Free format text: TRIAL NUMBER: 2018130000013; TRIAL DECISION FOR INVALIDATION REQUESTED 20180202

Effective date: 20180228

PJ1301 Trial decision

Patent event code: PJ13011S09D

Patent event date: 20180228

Comment text: Trial Decision on Final Judgment on Revocation

Appeal kind category: Invalidation

Request date: 20180202

Decision date: 20180228

Appeal identifier: 2018130000013

EXTG Ip right invalidated
PC2102 Extinguishment

Termination category: Others

Termination date: 20180601

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20180420

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2017100001359

Request date: 20170428

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20180420